volume 19 issue 6 pages 402-421

Clinical relevance of tumour-associated macrophages

Mikael J. Pittet 1, 2, 3, 4, 5, 6
Olivier Michielin 3, 6, 7
Denis Migliorini 3, 4, 5, 6
Publication typeJournal Article
Publication date2022-03-30
scimago Q1
wos Q1
SJR28.675
CiteScore114.5
Impact factor82.2
ISSN17594774, 17594782
Oncology
Abstract
In the past decade, substantial advances have been made in understanding the biology of tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A particular aspect that is becoming increasingly clear is that the interaction of TAMs with cancer cells and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. Therefore, manipulation of TAMs could enable improved disease control in a substantial fraction of patients across a large number of cancer types. In this Review, we examine the diversity of TAMs in various cancer indications and how this heterogeneity is being revisited with the advent of single-cell technologies, and then explore the current knowledge on the functional roles of different TAM states and the prognostic and predictive value of TAM-related signatures. We also review agents targeting TAMs that are currently being or will soon be tested in clinical trials, and how manipulations of TAMs can improve existing anticancer treatments. Finally, we discuss how TAM-targeting approaches could be further integrated into routine clinical practice, considering a precision oncology approach and viewing TAMs as a dynamic population that can evolve under treatment pressure. The interaction of tumour-associated macrophages (TAMs) with cancer and stromal cells in the tumour microenvironment enables and sustains most of the hallmarks of cancer. The authors of this Review examine the diversity of TAMs in various cancer indications, which is being revisited with the advent of single-cell technologies, and discuss the functional roles of different TAM states, the prognostic and predictive value of TAM-related signatures as well as approaches involving TAMs that are currently being or will soon be tested in clinical trials.
Found 
Found 

Top-30

Journals

5
10
15
20
25
30
Frontiers in Immunology
30 publications, 5.51%
Journal for ImmunoTherapy of Cancer
11 publications, 2.02%
Cancers
11 publications, 2.02%
Advanced Science
11 publications, 2.02%
Nature Communications
10 publications, 1.84%
International Journal of Molecular Sciences
10 publications, 1.84%
Frontiers in Oncology
8 publications, 1.47%
Molecular Cancer
7 publications, 1.29%
Cancer Cell
7 publications, 1.29%
ACS Nano
7 publications, 1.29%
Journal of Experimental and Clinical Cancer Research
7 publications, 1.29%
Scientific Reports
6 publications, 1.1%
Nature Reviews Cancer
5 publications, 0.92%
Biomaterials
5 publications, 0.92%
Advanced healthcare materials
5 publications, 0.92%
bioRxiv
5 publications, 0.92%
Cancer Letters
5 publications, 0.92%
Signal Transduction and Targeted Therapy
4 publications, 0.74%
Cells
4 publications, 0.74%
Journal of Hematology and Oncology
4 publications, 0.74%
Journal of Translational Medicine
4 publications, 0.74%
Cancer Science
4 publications, 0.74%
Advanced Materials
4 publications, 0.74%
Cell Reports
4 publications, 0.74%
Heliyon
4 publications, 0.74%
Biomedicines
4 publications, 0.74%
Cell Reports Medicine
4 publications, 0.74%
Journal of Controlled Release
4 publications, 0.74%
Biomarker Research
4 publications, 0.74%
5
10
15
20
25
30

Publishers

20
40
60
80
100
120
140
Springer Nature
126 publications, 23.16%
Elsevier
115 publications, 21.14%
Wiley
56 publications, 10.29%
Frontiers Media S.A.
46 publications, 8.46%
MDPI
41 publications, 7.54%
Cold Spring Harbor Laboratory
34 publications, 6.25%
Taylor & Francis
13 publications, 2.39%
BMJ
12 publications, 2.21%
American Chemical Society (ACS)
12 publications, 2.21%
American Association for Cancer Research (AACR)
11 publications, 2.02%
American Association for the Advancement of Science (AAAS)
9 publications, 1.65%
Oxford University Press
8 publications, 1.47%
Royal Society of Chemistry (RSC)
5 publications, 0.92%
American Society for Clinical Investigation
4 publications, 0.74%
Ovid Technologies (Wolters Kluwer Health)
3 publications, 0.55%
Research Square Platform LLC
3 publications, 0.55%
Spandidos Publications
3 publications, 0.55%
SAGE
3 publications, 0.55%
Hindawi Limited
2 publications, 0.37%
Mary Ann Liebert
2 publications, 0.37%
Public Library of Science (PLoS)
2 publications, 0.37%
eLife Sciences Publications
2 publications, 0.37%
The Endocrine Society
1 publication, 0.18%
Pharmaceutical Society of Japan
1 publication, 0.18%
Annual Reviews
1 publication, 0.18%
Pleiades Publishing
1 publication, 0.18%
Walter de Gruyter
1 publication, 0.18%
American Physiological Society
1 publication, 0.18%
20
40
60
80
100
120
140
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
544
Share
Cite this
GOST |
Cite this
GOST Copy
Pittet M. J. et al. Clinical relevance of tumour-associated macrophages // Nature Reviews Clinical Oncology. 2022. Vol. 19. No. 6. pp. 402-421.
GOST all authors (up to 50) Copy
Pittet M. J., Michielin O., Migliorini D. Clinical relevance of tumour-associated macrophages // Nature Reviews Clinical Oncology. 2022. Vol. 19. No. 6. pp. 402-421.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41571-022-00620-6
UR - https://doi.org/10.1038/s41571-022-00620-6
TI - Clinical relevance of tumour-associated macrophages
T2 - Nature Reviews Clinical Oncology
AU - Pittet, Mikael J.
AU - Michielin, Olivier
AU - Migliorini, Denis
PY - 2022
DA - 2022/03/30
PB - Springer Nature
SP - 402-421
IS - 6
VL - 19
PMID - 35354979
SN - 1759-4774
SN - 1759-4782
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Pittet,
author = {Mikael J. Pittet and Olivier Michielin and Denis Migliorini},
title = {Clinical relevance of tumour-associated macrophages},
journal = {Nature Reviews Clinical Oncology},
year = {2022},
volume = {19},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1038/s41571-022-00620-6},
number = {6},
pages = {402--421},
doi = {10.1038/s41571-022-00620-6}
}
MLA
Cite this
MLA Copy
Pittet, Mikael J., et al. “Clinical relevance of tumour-associated macrophages.” Nature Reviews Clinical Oncology, vol. 19, no. 6, Mar. 2022, pp. 402-421. https://doi.org/10.1038/s41571-022-00620-6.